March 2020

ONCOLOGY

FIRST PROSTATE CANCER THERAPY TO TARGET GENES DELAYS CANCER PROGRESSION

Featuring: Maha Hussain, MBChB

Episode Summary

For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, according to a large, international phase 3 trial. Maha Hussain, MD, Deputy Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University was one of the principal investigators of the PROfound trial is from Northwestern Medicine.​

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like